A reduction of brain temperature by 10 °C decreases ATP consumption by approximately 50%, which can double the time the brain can survive.The younger the person, the better the chances of survival. In one case, a child submerged in cold (37 °F (3 °C)) water for 66 minutes was resuscitated without apparent neurological damage. However, over the long term significant deficits were noted, including a range of cognitive difficulties, particularly general memory impairment, although recent magnetic resonance imaging (MRI) and magnetoencephalography (MEG) were within normal range. Children
Drowning is a major worldwide cause of death and injury in children. An estimate of about 20% of non-fatal drowning victims may result in varying degrees of ischemic and/or hypoxic brain injury. Hypoxic injuries refers to a lack or absence of oxygen in certain organs or tissues. Ischemic injuries on the other hand refers inadequate blood supply to certain organs or part of the body. These injuries can lead to an increased risk of long-term morbidity. Prolonged hypothermia and hypoxemia from nonfatal submersion drowning can result in cardiac dysrhythmias such as ventricular fibrillation, sinus bradycardia, or atrial fibrillation. Long-term neurological outcomes of drowning cannot be predicted accurately during the early stages of treatment. Although survival after long submersion times, mostly by young children, has been reported, many survivors will remain severely and permanently neurologically compromised after much shorter submersion times.
The effect it may have on the baby is still unknown.There is limited data regarding the safety of taking paromomycin while breastfeeding but because the drug is poorly absorbed minimal amounts of drug will be secreted in breastmilk. HIV/AIDS
There is limited evidence that paromomycin can be used in persons coinfected with HIV and Cryptosporidium. A few small trials have showed a reduction in oocyst shedding after treatment with paromomycin. Adverse effects
The most common adverse effects associated with paromomycin sulfate are abdominal cramps, diarrhea, heartburn, nausea, and vomiting. Long-term use of paromomycin increases the risk for bacterial or fungal infection. Signs of overgrowth include white patches in the oral cavities. Other less common adverse events include myasthenia gravis, kidney damage, enterocolitis, malabsorption syndrome, eosinophilia, headache, hearing loss, ringing in the ear, itching, severe dizziness, and pancreatitis. Interactions
Paromomycin belongs to the aminoglycoside drug class and therefore are toxic to the kidneys and to ears. These toxicities are additive and are more likely to occur when used with other drugs that cause ear and kidney toxicity. Concurrent use of foscarnet increases the risk of kidney toxicity. Concurrent use of colistimethate and paromomycin can cause a dangerous slowing of breathing known as respiratory depression, and should be done with extreme caution if necessary. When used with systemic antibiotics such as paromomycin, the cholera vaccine can cause an immune response. Use with strong diuretics, which can also harm hearing, should be avoided.